Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA

When it comes to experimental cholesterol drugs, all eyes this year are on inclisiran, the $9.7 billion RNAi drug Novartis hopes will replace and vastly outsell Regeneron and Amgen’s PCSK9 inhibitors.